Targeted drug therapy of CLL with Ven-O is associated with a reduction in the number of geriatric conditions as a surrogate of frailty. See Figure 2B in the article by van der Straten et al that begins on page 1131.
Targeted drug therapy of CLL with Ven-O is associated with a reduction in the number of geriatric conditions as a surrogate of frailty. See Figure 2B in the article by van der Straten et al that begins on page 1131.
